NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $3.71 -0.06 (-1.59%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Sutro Biopharma Stock (NASDAQ:STRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$3.70▼$3.8150-Day Range$3.12▼$5.0152-Week Range$2.01▼$6.13Volume313,327 shsAverage Volume830,233 shsMarket Capitalization$303.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.13Consensus RatingBuy Company OverviewSutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed on Monday at midnight.Click here to watch it now. Sutro Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 89% of companies evaluated by MarketBeat, and ranked 139th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSutro Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($2.96) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sutro Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.50% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 4.35%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted3.50% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 4.35%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.65 News SentimentSutro Biopharma has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search Interest2 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Stock News HeadlinesSutro Biopharma (NASDAQ:STRO) Earns "Overweight" Rating from Piper SandlerOctober 14 at 3:35 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Sutro Biopharma (NASDAQ:STRO)October 13, 2024 | americanbankingnews.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 17, 2024 | Porter & Company (Ad)Sutro Biopharma: Poised to Become an ADC Powerhouse with Innovative XpressCF(+) PlatformOctober 12, 2024 | markets.businessinsider.comSutro Biopharma’s Promising ADC Innovations and Strategic Collaborations Justify a Buy RatingOctober 12, 2024 | markets.businessinsider.comTruist Financial Issues a Buy Rating on Sutro Biopharma (STRO)October 11, 2024 | markets.businessinsider.comSutro Biopharma (STRO) Gets a Buy from WedbushOctober 11, 2024 | markets.businessinsider.comSutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumOctober 10, 2024 | globenewswire.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $4.29 on January 1st, 2024. Since then, STRO shares have decreased by 13.5% and is now trading at $3.71. View the best growth stocks for 2024 here. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) released its earnings results on Tuesday, August, 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.20. The firm had revenue of $25.71 million for the quarter, compared to analysts' expectations of $26.28 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 102.06% and a negative net margin of 73.48%. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Top institutional investors of Sutro Biopharma include Exchange Traded Concepts LLC (0.06%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Nicki Vasquez, William J Newell and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/13/2024Today10/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$12.13 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+226.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,790,000.00 Net Margins-73.48% Pretax Margin-63.06% Return on Equity-102.06% Return on Assets-29.12% Debt Debt-to-Equity RatioN/A Current Ratio3.41 Quick Ratio3.41 Sales & Book Value Annual Sales$169.36 million Price / Sales1.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book1.51Miscellaneous Outstanding Shares81,794,000Free Float77,128,000Market Cap$303.46 million OptionableOptionable Beta1.17 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:STRO) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.